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Abstract
Background: Moxibustion is a traditional Chinese method that uses the heat generated by burning herbal 
preparations containing Artemisia vulgaris to stimulate acupuncture points. Considering moxibustion is closely related 
to acupuncture, it seems pertinent to evaluate the effectiveness of moxibustion as a treatment of symptoms of cancer. 
The objective of this review was to systematically assess the effectiveness of moxibustion for supportive cancer care.
Methods: We searched the literature using 11 databases from their inceptions to February 2010, without language 
restrictions. We included randomised clinical trials (RCTs) in which moxibustion was employed as an adjuvant 
treatment for conventional medicine in patients with any type of cancer. The selection of studies, data extraction, and 
validations were performed independently by two reviewers.
Results: Five RCTs compared the effects of moxibustion with conventional therapy. Four RCTs failed to show 
favourable effects of moxibustion for response rate compared with chemotherapy (n = 229, RR, 1.04, 95% CI 0.94 to 
1.15, P = 0.43). Two RCTs assessed the occurrence of side effects of chemotherapy and showed favourable effects of 
moxibustion. A meta-analysis showed significant less frequency of nausea and vomiting from chemotherapy for 
moxibustion group (n = 80, RR, 0.38, 95% CIs 0.22 to 0.65, P = 0.0005, heterogeneity: χ2 = 0.18, P = 0.67, I2 = 0%).
Conclusion: The evidence is limited to suggest moxibustion is an effective supportive cancer care in nausea and 
vomiting. However, all studies have a high risk of bias so effectively there is not enough evidence to draw any 
conclusion. Further research is required to investigate whether there are specific benefits of moxibustion for supportive 
cancer care.
Background
Most cancer patients experience multiple symptoms
related to either the cancer itself or late treatment effects
[1]. The frequently experienced and severe adverse events
associated with such treatments lead patients to seek sup-
portive complementary and alternative medicine (CAM)
[2]. Most patients use CAM as an adjunct to conventional
treatments [3-5]. Acupuncture type interventions are one
of the most popular forms of CAM [6]. It is now a widely
accepted intervention for the treatment of a variety of
conditions [7]. Several reviews claim that acupuncture
offers therapeutic benefits for cancer patients [8-10].
Moxibustion is a traditional Chinese method that uses
the heat generated by burning herbal preparations con-
taining  Artemisia vulgaris to stimulate acupuncture
points [11]. There are two types of moxibustion. Direct
moxibustion is applied directly to the skin surface at the
acupuncture point [11]. In indirect moxibustion some
insulating materials (ginger, salts and etc) were placed
between the moxa cone and the skin [11]. Considering
moxibustion is closely related to acupuncture, it seems
pertinent to evaluate the effectiveness of moxibustion as
a treatment of symptoms of cancer. Several reviews of
moxibustion for cancer care are currently available [12-
16]. However, most of these review failed to employ sys-
tematic and transparent methods and are open to bias
[12,14-16]. Furthermore, they did not focus on moxbus-
tion and do not provide specific evidence for moxibustion
during cancer care. One overview [13], was not also com-
prehensive and open to selection bias. Currently, no sys-
tematic review of this subject is available. The aim of this
systematic review was to critically evaluate all of cur-
rently available randomised clinical trials regarding the
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effectiveness of any type of moxibustion as adjunct ther-
apy during cancer care.
Methods
Data sources
The following databases were searched from inception
through to February 2010: MEDLINE, EMBASE,
CINAHL, PychInfo, five Korean Medical Databases
(Korean Studies Information, DBPIA, Korea Institute of
Science and Technology Information, KoreaMed, and
Research Information Center for Health Database), Chi-
nese Medical Database (China National Knowledge
Infracture: CNKI), The Cochrane Library 2010, Issue 1
and Japan Science and Technology Information
Aggreator, Electronic (J-STAGE). The search terms were
used as follows: (moxibustion OR moxa*) AND (cancer
OR metasta$ OR carcinoma OR oncolo$ OR malignan$)
in Korean, Chinese, or English. Reference lists of all
obtained papers were searched in addition. We also per-
f o r m ed  e l ec t r o n i c  s e a r c h e s  o f  r e l ev a n t  j o u r n a l s  ( F A CT
[Focus on Alternative and Complementary Therapies],
and Research in Complementary Medicine [Forschende
Komplementarmedizin] up to January 2010) through
their website. Further, our own personal files were manu-
ally searched. Hardcopies of all articles were obtained and
read in full.
Study selection
Prospective randomised clinical trials (RCTs) were
included if moxibustion was used as the sole treatment or
as an adjunct to other treatments for patients having any
type of cancer (if the control group also received the same
concomitant treatments as the moxibustion group) and if
clinically relevant outcomes were assessed. Trials with
designs that did not allow an evaluation of efficacy of the
test intervention (eg, by using a treatments of unproven
efficacy in the control group or comparing two different
f o rm s  o f  m o x i b us t i o n )  w e r e  e x c l u d ed .  T ria l s  w e r e  a ls o
excluded if only immunological or biological parameters
were accessed. Trials published in the forms of disserta-
tion and abstract were included. No language restrictions
were imposed.
Data extraction and assessment of risk of bias
Hard copies of all articles were obtained and read in full.
All articles were read by three independent reviewers
(MSL, TYC, SSL) and data from the articles were vali-
dated and extracted according to pre-defined criteria
(Table 1). No language limitations were imposed.
Risk of bias was assessed using the Cochrane classifica-
tion in four criteria: sequence generation, blinding,
incomplete outcome measures, and allocation conceal-
ment [17]. Considering that it is hard to blind therapists
to the use of moxibustion, we assessed patient and asses-
sor blind separately. If it is patient-assessed pain then it is
not possible to assessor blind because the patient himself
would be the assessor. The assessor needs to be a differ-
ent person. Thus, if pain is assessed by another person
(not the patient himself) then assessor blinding would be
possible. Disagreements were resolved by discussion
between the two reviewers (MSL, TYC). There were no
disagreements between the three reviews about the risk
of bias.
Data synthesis
To summarise the effects of moxibustion on outcomes
(response rate), we abstracted the risk estimates (relative
risk: RR) and and 95% confidence interval (CI) was calcu-
lated using the Cochrane Collaboration's software
(Review Manager (RevMan) Version 5.0 for Windows.
Copenhagen: The Nordic Cochrane Centre). For studies
with insufficient information, we contacted the primary
authors to acquire and verify data where possible. If
appropriate, we then pooled the data across studies using
random effects models (if excessive statistical heteroge-
neity did not exist). The chi-square test, and the Higgins
I2 test were used to assess heterogeneity.
Results
Study description
The searches identified 515 potentially relevant articles of
which 510 studies were excluded (Figure 1). Key data of
the included 5 RCTs are summarized in Table 1[18-22].
All trials originated from China. Three [18,19,22] of the
included trials had a two-armed, parallel group design
and two RCTs [20,21] used a 3-armed parallel group
design. The types of cancer treated within the trials were
gastric cancer [20], nasopharyngeal carcinoma [18,19],
and various cancers [21,22]. The objective outcome mea-
sures were survival rate [19], response rate [18-21], and
side effects of chemotherapy [19,20], and quality of life
[21,22]. None of the included RCTs reported the rationale
for selecting treatment points. All RCTs employed indi-
rect moxibustion.
Risk of bias
The most of included trials had high risk of bias. One
RCT [19] employed appropriate sequence generation.
None described incomplete outcome measures One
study reported details about allocation concealment [19].
None assessed the adverse events from moxibustion.
Outcomes
Response rate
Four RCTs reported response rate for moxibustion as an
adjunctive of chemotherapy compared with chemother-
apy [18-21]. All of 4 RCTs failed to show favourable


























































































Table 1: Summary of parallel open, randomised clinical studies of moxibustion for cancer
First author (year) Sample size
Condition
Intervention group (Regimen) Control group
(Regimen)
Main outcomes Intergroup differences Treated acupuncture 
points
Rationale for point 
selection
Cheng (2005) [18] 84
Nasopharyngeal 
carcinoma
(A) Moxibustion (once daily for 30 
days, n = 42), plus radiotherapy and 
chemotherapy
Indirect
(B) Chemotherapy and 
radiotherapy, plus drug 
therapies for side effects 
(n = 42)
Response rate NS, 1.05 [0.95, 1.16] CV8
n.r.
Chen (2000) [19] 56
Nasopharyngeal 
carcinoma
(A) Moxibustion (once daily for 30 
days, n = 28), plus (B)
Indirect
(B) Chemotherapy and 
radiotherapy (n = 28), 
plus drug therapies for 
side effects
1) Response rate
2) Side effect of 
chemotherapy3) 5-year 
survival rate
1) NS, 1.10 [0.83, 1.44]
2) P < 0.05 in favour of A
3) NS, 1.40 [0.75, 2.60]
CV8
n.r.
Cao (1997) [20] 36
Gastric cancer
(A) Moxibustion (3 times weekly, 
n.r, n = 12), plus (B)
Indirect
(B) Chemotherapy(n = 12)
(C) Chemotherapy plus 
drug therapies for side 
effects (n = 12)
1) Response rate
2) Side effect of 
chemotherapy
1) NS, 2.0 [0.82, 2.34]
2) P < 0.05 in favour of A
CV8
n.r.
Liu (2001) [21] 81
Various cancer
(Malignant tumor)
(A) Moxibustion (once daily, n.r, n = 
30), plus (B)
Indirect
(B) Chemotherapy (n = 
35), plus herbal medicine 
(Gubenyiliu III 400 ml, 
twice a day)
(C) Chemotherapy (n = 16)
1) Response rate
2) Living quality
1) NS, 0.99 [0.87, 1.12]
2) NS, 0.22 [-0.27, 0.71]
GV14, BL17, ST36
n.r.
Bian (2004) [22] 44
Various cancer (cancer 
pain)
(A) Moxibustion (2-3 times daily for 
20 days, n = 23), plus morphine 
injection (acupoint, 5-10 mg, twice 
a day)
Indirect
(B) Morphine injection 
(10-20 mg, 2-3 times a 
day, n = 21)
Living quality P < 0.00001, 2.03 [1.29, 
2.78] in favour of A
GV14, CV4, ST36, LI4, ashi-
point
n.r.
NS: not significant; n.r.: not reportedLee et al. BMC Cancer 2010, 10:130
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Figure 1 Flowchart of trial selection process. RCT: randomized clinical trial; CCT: controlled clinical trial; UOSs: uncontrolled observational studyLee et al. BMC Cancer 2010, 10:130
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sis also suggested not significant difference between two
groups (n = 229, RR, 1.04, 95% CI 0.94 to 1.15, P = 0.43,
heterogeneity: χ2 = 4.06, P = 0.26, I2 = 26%, Figure 2A).
Subanalysis also failed to show favourable effects of mox-
ibustion on response rate in patients with nasopharyn-
geal carcinoma (n = 140, RR, 1.06, 95% CIs 0.96 to 1.16, P
= 0.24, heterogeneity: χ2 = 0.12, P = 0.73, I2 = 0%, Figure
2A) [18,19].
Side effect of chemotherapy
Two RCTs assessed the occurrence of side effects of che-
motherapy [19,20]. Both studies showed favourable
effects of moxibustion plus chemotherapy compared with
chemotherapy. A meta-analysis showed significant less
frequency of nausea and vomiting from chemotherapy for
moxibustion group (n = 80, RR, 0.38, 95% CIs 0.22 to
0.65, P = 0.0005, heterogeneity: χ2 = 0.18, P = 0.67, I2 = 0%,
Figure 2B).
Quality of life
Two RCTs tested the effects moxibustion on quality of life
compared with chemotherapy or morphine injection
[21,22]. One RCT [22] showed favourable effects of moxi-
bustion compared with morphine injection, while other
RCT [21] failed to generate positive effects compared
with chemotherapy.
Discussion
This systematic review identified only very few RCTs for
moxibustion. Their results fail to provide convincing evi-
dence for the effectiveness of moxibustion. However, two
RCTs demonstrate that moxibution as an adjunctive ther-
apy is more effective for reduction of side effects (from
chemotherapy) than chemotherapy alone [19,20], specifi-
cally for nausea and vomiting. In the present set of stud-
ies, an absence of adequate statistical analysis of the
variability of therapeutic protocols and poor quality of
reporting are frequent methodological problems. Collec-
tively, the current evidence from RCTs of moxibustion as
supportive cancer care is not convincing. However, the
number of trials and the total sample size and their meth-
odological quality are too low to draw firm conclusions.
Figure 2 A forest plot of moxibustion for cancer care. (A) treating cancer, showing the response rate for moxibustion plus chemotherapy vs. che-
motherapy; (B) side effects.Lee et al. BMC Cancer 2010, 10:130
http://www.biomedcentral.com/1471-2407/10/130
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The risk of bias in the studies was assessed based on the
descriptions of sequence generation, blinding, incom-
plete outcome data, and allocation concealment. All of
the studies were burdened with a high risk of bias. One
RCT [19] employed allocation concealment and none of
the RCTs made an attempt to blind assessors. One RCT
[19] reported details of drop-outs and withdrawals, while
the others didn't describe that may have led to exclusion
or attrition biases. Thus the reliability of the evidence
presented is clearly limited.
All of included trials c om par ed indirect mo xibustion
with chemotherapy or morphine. The fact that there is no
good trial evidence in support of moxibustion is in line
with several different interpretations. Moxibustion may
be ineffective, the studies may have been incorrectly
designed or the treatment may not have been adminis-
tered optimally in the existing studies. In the absence of a
sufficient number of RCTs, other types of evidence might
be helpful. Two controlled trials reported positive effects
of moxibustion compared with chemotherapy, drug or no
treatment in cancer patients [23,24]. Uncontrolled trials
also imply that moxibustion is beneficial for symptom
management of various cancers [25-29]. Unfortunately,
such data are highly susceptible to bias and hence, they
provide little useful information on the specific effects of
moxibustion as it relates to supportive cancer care.
One argument for using moxubustion for the support-
i ve  ca r e  f or  canc e r m igh t  be  t ha t  it  is  sa f e r t ha n dru g
treatment. None of included trials assessed adverse
events. Currently 3 studies evaluated the adverse events
or possible risks of moxibution [30-32]. Mild or no
adverse effects of were noted in previous reports [30,32],
while one study [31] concerned possible hazardous in
health by smoke from mouldering moxibustion. Relative
to those of other conventional treatments, these are mild,
infrequent and perhaps even negligible. Further study is
needed to clarify this.
Assuming that moxibustuon is beneficial for cancer
patients, possible mechanisms of action are of interest.
Moxibustion may exert not only absorption of extract
from moxa on acupuncture points but also direct effects
due to acupuncture point stimulation from heat. Some
aspect of mechanism may be similar that of acupuncture.
One of them is that moxibustion may influence the multi-
ple cortical, subcortical/limbic, and brainstem areas [33-
37]. Involving these modulation therapeutic effects of
moxibustion may mediate partially through opioidergic
and/or monoaminergic neurotransmission [35,38]. Acu-
puncture often evokes complex somatosensory sensa-
tions and may modulate the cognitive/affective
perception of pain, suggesting that many effects are sup-
ported by the brain and extending central nervous system
networks [36,39,40]. Another possible mechanism
includes an influence on the heat shock proteins and the
function of immune cells. It has been shown that moxi-
bustion up-regulated heat shock protein 70 and
decreased the gastric injury and apoptosis of gastric
mucosal cells [41]. The third hypothesis is that the moxi-
bustion improves the function of immune cells. Moxibus-
tion induced higher cellular immune function and
increased the content of β-endorphin in the lymphocyte
of the spleen in HAC cancer mice [42]. Moxibustion may
modulate immunity through neurohormonal regulatory
mechanism. Moxibustion also inhibited the growth of
tumor and enhanced cellular immune functions via
cytokine production (IL-2 or IL-12) [43] and increase of
natural killer cell activity in tumor-bearing mice [44].
None of these theories are, however, currently fully estab-
lished.
One could also argue about the value of conducting sys-
tematic reviews or meta-analyses of a limited number of
included studies. They can increase power, improve pre-
cision, answer questions not asked by individual studies,
settle controversies arising from conflicting results,
improve the quality of future primary studies, and gener-
ate new hypotheses [45-47]. Systematic review can also
avoid biases and make results and conclusions as objec-
tive as possible [46]. Even systematic reviews that find no
primary studies to include can be valuable in that they
may point towards important gaps in our knowledge.
However, systematic reviews are retrospective and
strongly depend on the quality of the primary studies
[46]. They may also lead to contradictory overall conclu-
sions [46]. The use of statistics does not guarantee that
the results are valid. In our case, as the conclusions from
the meta-analyses are from only 4 RCTs, the conclusions
must remain tentative.
Limitations of our systematic review pertain to the
potential incompleteness of the evidence reviewed. We
aimed to identify all studies on the topic. The distorting
effects of publication bias and location bias on systematic
reviews are well documented [48-50]. In the present
review there were no restrictions on the review publica-
tion language, and a large number of different databases
were searched. We are therefore confident that our
search strategy located all relevant data on the subject.
Most of the included RCTs that reported positive results
come from China, a country which has been shown to
produce no negative results [51]. Further limitations
include the paucity and the often suboptimal quality of
the primary data.
Conclusion
The evidence is limited to suggest moxibustion is an
effective supportive cancer care in nausea and vomiting.
However, all studies have a high risk of bias so effectively
there is not enough evidence to draw any conclusion. Fur-
ther research is required to investigate whether there areLee et al. BMC Cancer 2010, 10:130
http://www.biomedcentral.com/1471-2407/10/130
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specific benefits of moxibustion for supportive cancer
care.
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